CLLS: Bad News

Cellectis reports patient death in first clinical trial w/UCART123. Expect sharp sell-off today:
http://www.businesswire.com/news/home/20170904005410/en/Cell…

2 Likes

So far Cellectis is down 26% on Paris exchange. Cytokinine Release Syndrome is once again the culprit, as it also was with KITE. Cellectis trial w/UCART123 put on pause by FDA in order to readjust tx dosage downward to try to prevent this side effect.

2 Likes

It is important to note from the BusinessWire feed that no Graft v. Host reaction was detected in either of the first two patients receiving UCART123. This implies that the “universal donor” T-cells that the patients received via infusions were not attacking the patients’ tissues. So, I take this as a bit of good news.